Pompe disease (PD), a glycogen storage inborn error of metabolism (type II), is caused by the deficiency of acid α-glucosidase (GAA); it can manifest itself in two forms: infantile onset (IPD) and late-onset (LOPD). Clinical presentation of this disorder is variable, depending on age at onset, level of organ involvement, progression rate, and genotype. PD is classifi ed as a glycogenosis; and, since individuals with this disorder excrete oligosaccharides in the urine, can be considered to be an oligosaccharidosis as well. Urinary tetraglucoside (Glc 4 ), considered to be a biomarker of the disease, could be an auxiliary tool in screening for PD in suspected cases. Urine samples from 24 known patients with IPD (n = 15) and LOPD (n = 9), and normal controls (n = 215) were submitted to thin layer chromatography (TLC) analysis and high performance liquid chromatography (HPLC) quantifi -
). An inverse correlation of Glc 4 excretion with therapy duration was observed in both cases. Furthermore, systematic quantifi cation of Glc 4 by HPLC showed that the reduction of Glc 4 levels in these two patients fl uctuated according to clinical outcome complications or treatment interruption. Routine screening for PD can be performed by these two methods, and quantifi cation of Glc 4 by HPLC proved to be a very useful and sensitive tool in monitoring patients on ERT.
